King s Research Portal

Similar documents
King s Research Portal

King s Research Portal

Aortic valve implantation using the femoral and apical access: a single center experience.

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

Accepted Manuscript. Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial. Saina Attaran, MD, Vinod H.

King s Research Portal

Percutaneous Therapy for Calcific Mitral Valve Disease

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic

TAVR: Echo Measurements Pre, Post And Intra Procedure

King s Research Portal

Boston, MA 2 Service Chief, Cardiovascular Imaging, Department of Radiology, Massachusetts General Hospital,

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

The EARNEST study : interarm blood pressure differences should also be recorded Moody, William; Ferro, Charles; Townend, Jonathan

The Journal of Thoracic and Cardiovascular Surgery

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement

TAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min

Accepted Manuscript. A Bad Trade: Mitral Regurgitation for Mitral Stenosis and Atrial Fibrillation

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

Echo Assessment Pre-TAVI

New imaging modalities for assessment of TAVI procedure and results. R Dulgheru, MD Heart Valve Clinic CHU, Liege

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Pre-procedural CT angiography for Transcatheter Aortic Valve Implantation: What a Radiologist Needs to Know?

Aortic Stenosis: Background

3D Printing & Echocardiography

Optimal Imaging Technique Prior to TAVI -Echocardiography-

7 th Conference of Transcatheter Heart Valve Therapies

Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

*Core lab for numerous trials, for which I receive no direct compensation from sponsors.

3D Printing & Echocardiography

TAVR for low-risk patients in 2017: not so fast.

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

Jonathon Leipsic MD FRCPC FSCCT. Vice Chairman of Radiology University of British Columbia. Disclosures

Conflict of Interests

Procedural Guidance of TAVR: How to Assure it Goes Right and What to Do If It Doesn t

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

NEXT-GENERATION TAVR. A look at the future of percutaneous valve replacement.

Corrado Tamburino, MD, PhD

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

The Role of Imaging in Transcatheter Aortic Valve Implantation

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Progress In Transcatheter Aortic Valve Implantation

Transcatheter aortic valve implantation for severe aortic stenosis a new paradigm for multidisciplinary intervention: A prospective cohort study

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

King s Research Portal

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

Accepted Manuscript. MAC: Mitral Annular Calcification or a Modern Approach to Concept learning in surgery

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

TAVI EN INSUFICIENCIA AORTICA

TAVR: It s a Career, Not Just a Procedure! Jeffrey A Southard, MD Cardiology May 5, 2012

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504

Transcatheter Aortic Valve Implantation as a Bailout Procedure for Acute Aortic Valve Regurgitation During Endovascular Arch Repair

The Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy

Commentary:Right Ventricular-Tricuspid Valve Interdependance And The Challenges For Structural Heart Valve Therapy

Paravalvular Regurgitation is a Risk Factor Following TAVI

TAVI Implantation: Rapid Pacing, Pre and Post Dilatation

Transcatheter valve-in-valve implantation for degenerated surgical bioprostheses

DISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.

Policy Specific Section: March 30, 2012 March 7, 2013

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement With the St. Jude Medical Portico Valve

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

Section 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient

Transcatheter Aortic Valve Replacement (TAVR)

Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques

What is TAVR? Transcatheter Aortic Valve Replacement

Preprocedural evaluation for TAVR

Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis

The Journal of Thoracic and Cardiovascular Surgery

Aortic valve calcium load before TAVI: Is it important?

TAVR IN INTERMEDIATE-RISK PATIENTS

Bioprosthetic aortic valve replacement: a high standard of comparison for transcatheter aortic valve implantation

Pacemaker rates Second generation TAVI Devices

Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR)

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012

Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Aortic Valve Stenosis and TAVR: Putting it all together.

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

SAPIEN 3 Sizing Considerations:

Transcatheter Aortic Valve Replacement with Evolut-R

Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,

Dr Winnie Sze-Wun Chan. Cardiac Team Deputy Team Head Department of Radiology and Imaging Queen Elizabeth Hospital Hong Kong

Transcatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves

One-year outcomes with the transcatheter LOTUS Edge Aortic Valve System

Echocardiographic Evaluation of Aortic Valve Prosthesis

TAVR Valve Thrombosis

CoreValve in a Degenerative Surgical Valve

Stainless Steel. Cobalt-chromium

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

Transcription:

King s Research Portal DOI: 10.1016/j.amjcard.2016.03.028 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Eskandari, M., Aldalati, O., Byrne, J., Dworakowski, R., Wendler, O., Alcock, E.,... MacCarthy, P. (2016). Zero Contrast Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using Fluoroscopy-Echocardiography Fusion Imaging. American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2016.03.028 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim. Download date: 17. Mar. 2019

Accepted Manuscript Zero Contrast Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using Fluoroscopy-Echocardiography Fusion Imaging Mehdi Eskandari, MD, Omar Aldalati, MD, Jonathan Byrne, MBChB, PhD, Rafal Dworakowski, MD, PhD, Olaf Wendler, MD, PhD, Ema Alcock, MBBS, Mark Monaghan, PhD, Philip MacCarthy, BSc MBChB, PhD. PII: DOI: Reference: AJC 21769 S0002-9149(16)30374-5 10.1016/j.amjcard.2016.03.028 To appear in: The American Journal of Cardiology Received Date: 7 February 2016 Accepted Date: 14 March 2016 Please cite this article as: Eskandari M, Aldalati O, Byrne J, Dworakowski R, Wendler O, Alcock E, Monaghan M, MacCarthy P, Zero Contrast Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using Fluoroscopy-Echocardiography Fusion Imaging, The American Journal of Cardiology (2016), doi: 10.1016/j.amjcard.2016.03.028. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Zero Contrast Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using Fluoroscopy-Echocardiography Fusion Imaging Short Title: Zero Contrast TAVR Mehdi Eskandari, MD, Omar Aldalati MD, Jonathan Byrne, MBChB, PhD, Rafal Dworakowski, MD, PhD, Olaf Wendler, MD, PhD, Ema Alcock, MBBS, Mark Monaghan, PhD, Philip MacCarthy BSc MBChB, PhD. King s College Hospital, London, UK Corresponding Author: Mehdi Eskandari Suit 6, Golden Jubilee Building King s College Hospital Denmark Hill London UK, SE59RS Phone: 00447903798465 Email: Mehdi.Eskandari@nhs.net

Acute kidney injury (AKI) remains a major concern in the field of TAVR and is associated with increased mortality, up to 2-8 fold (1). Although the exact mechanism of post-tavr AKI is unknown and seems to be multifactorial, contrast has been reported as a contributing factor (2). During TAVR, contrast is used for conventional aortic root angiography, for positioning of the TAVR valve device and assessing the peripheral vasculature. To our knowledge, for the first time we report transfemoral TAVR performed with zero contrast using fluoroscopy and ultrasound guidance. This was done in two patients with symptomatic, severe aortic stenosis and significant chronic kidney disease (stage III) who were deemed high risk for surgical aortic valve replacement after discussion in the multidisciplinary Heart Team meeting. EchoNavigator system (Phillips Healthcare, Netherland) is a novel imaging technology which allows fusion of real time 2D and 3D echocardiography images on the fluoroscopy screen. It has the ability to identify the optimal perpendicular valve view without use of contrast (Figure 1), can provide a road map to assist crossing of the aortic valve in difficult cases and enables overlay of echocardiographic images on the X-ray screen so that the the soft tissue characterization of echocardiography is combined with excellent device visualization of X- ray to assure precise device deployment. Determining the optimal valve view is a crucial prerequisite for accurate positioning of the bioprosthetic valve to avoid potentially lifethreatening complications. Although aortic root angiography is conventionally used to identify the valve view, EchoNavigator can be solely used for this purpose. Moreover, to further minimise exposure to contrast, 3D transesophageal echocardiography (TEE), which is the standard technique in our centre, was used for valve sizing. Procedures were done under general anesthesia. As per routine practice in our centre, we used a handheld ultrasound device for establishing vascular access in both patients which also

allowed assessment of patency of the femoral arteries at the end of the procedure without the use of contrast. For the first patient, a 27 mm Lotus valve (Boston Scientific) was positioned under combined fluoroscopy and fusion imaging guidance (Figure 2). Intra procedural 2D colour Doppler assessment of the positioned valve revealed mild to moderate paravalvular aortic regurgitation (AR) resulting from under-expansion of the valve at the site of severely calcified non-coronary cusp. Despite attempts to reposition the valve, the paravalvular AR remained unchanged. Although there is very limited data on post dilatation of the Lotus valve (3), based on previous successful experience in our centre, we decided to post dilate using a 24 mm balloon, which resulted in complete resolution of the paravalvular AR. A 26 mm Sapien 3 (Edwards Lifesciences) valve was used for the second case and deployed under fluoro-echo fusion imaging with no parvalvular AR assessed by TEE at the end of the procedure (Figure 3). A thorough echocardiographic assessment was performed at the end of each procedure to exclude new regional wall motion abnormalities. Both patients had an excellent post-procedure recovery and were discharged home on day three with no change in renal function, no residual trans-aortic valvular gradient and no paravalvular AR. Fluoro-echo fusion imaging can be used to minimise the contrast use in patients at high risk of developing AKI. The technique has the potential to be routinely used in performing TAVR with zero contrast. Further studies are required to assess the impact of zero contrast strategy on patients outcome. Mehdi Eskandari MD Omar Aldalati MD Jonathan Byrne PhD Rafal Dworakowski MD, PhD

Olaf Wendler, MD, PhD Ema Alcock, MBBS Mark Monaghan PhD Philip MacCarthy PhD London, United Kingdom 10 February 2016

References 1. Najjar M, Salna M, George I. Acute kidney injury after aortic valve replacement: incidence, risk factors and outcomes. Expert Rev Cardiovasc Ther 2015;13:301-316. 2. Elhmidi Y, Bleiziffer S, Deutsch MA, Krane M, Mazzitelli D, Lange R, Piazza N. Acute kidney injury after transcatheter aortic valve implantation: incidence, predictors and impact on mortality. Arch Cardiovasc Dis 2014;107:133-139. 3. Fuchs F, Tiyerili V, Roell W, Grube E, Werner N, Nickenig G, Sinning JM. Successful post-dilation of a lotus transcatheter aortic valve in a case of prosthesis frame underexpansion due to leaflet calcification. JACC Cardiovasc Interv 2015;8:866-868.

No of figures: 3 (all colour) Figure captions: Figure 1. Identifying the valve view by EchoNavigator Figure 2. Positioning of the Lotus valve using EchoNavigator. Figure 3. Positioning of the Sapien 3 valve using EchoNavigator. Figure 1 legend. After probe registration, a bi-plane echocardiographic view of the aortic valve is acquired. The annulus is marked in two perpendicular views. The Free view of EchoNavigator is rotated such that the annulus will look like a line, representing aligned aortic valve sinuses. The valve view is shown at the right lower corner of the screen. Figure 2 legend. Fused real time 3D TEE image on the X-ray screen can be used for positioning of the TAVR valve in combination with fluoroscopy. Red line represents annulus, blue arrows: aortic valve leaflets, green arrow: Lotus valve radiopaque marker. Figure 3 legend. Positioning of the Sapien 3 valve using fluoro-echo fusion imaging. Red arrows: aortic valve leaflets, blue arrow: Sapien valve radiopaque marker.